Thermo Fisher Scientific completed the acquisition of CorEvitas from Audax Private Equity for $913m.

Thermo Fisher Scientific, a supplier of scientific instrumentation, completed the acquisition of CorEvitas, a provider of regulatory-grade, real-world evidence for approved medical treatments and therapies, from Audax Private Equity, an investment firm, for $913m. “We are very excited to welcome our new CorEvitas colleagues to Thermo Fisher. CorEvitas expands our clinical research business with highly complementary real-world evidence solutions, which is an increasingly important area and will help to enhance decision-making as well as the time and cost of drug development. We are excited by the opportunity to further accelerate innovation and advance productivity for our pharma and biotech customers in their work to deliver new medicines and therapeutics to benefit patients,” Marc N. Casper, Thermo Fisher Chairman, President and CEO.